|Application ||WB, IHC-P, E|
|Other Accession||Q8BH27, NP_001073966.2|
|Calculated MW||62984 Da|
|Antigen Region||521-549 aa|
|Other Names||Multiple epidermal growth factor-like domains protein 9, Multiple EGF-like domains protein 9, Epidermal growth factor-like protein 5, EGF-like protein 5, MEGF9, EGFL5, KIAA0818|
|Target/Specificity||This MEGF9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 521-549 amino acids from the C-terminal region of human MEGF9.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||MEGF9 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MEGF9 (multiple EGF-like-domains 9) is a novel transmembrane protein with multiple EGF-like repeats, which is predominantly expressed in the developing and adult CNS (central nervous system) and PNS (peripheral nervous system). The domain structure of MEGF9 consists of an N-terminal region with several potential O-glycosylation sites followed by five EGF-like domains, which are highly homologous with the short arms of laminins. Following one single pass transmembrane domain, a highly conserved short intracellular domain with potential phosphorylation sites is present.
Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :
Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)
Nakayama, M., et al. Genomics 51(1):27-34(1998)
If you have any additional inquiries please email technical services at email@example.com.